LobbyingTravere Therapeutics lobbying by quarter
Travere Therapeutics TVTX's latest lobbying report covers Q2 2026, at $226K. The four quarters Q4 2025–Q3 2026 total $908K. Its first report covers Q2 2021; the issues it reports most are Pharmacy and Health Issues.
Travere TherapeuticsTVTX
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $908K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2021
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2021 | $7,500 | 1 |
| Q3 2021 | $0 | 0 |
| Q4 2021 | $0 | 0 |
| Q1 2022 | $0 | 0 |
| Q2 2022 | $0 | 0 |
| Q3 2022 | $0 | 0 |
| Q4 2022 | $325K | 5 |
| Q1 2023 | $285K | 4 |
| Q2 2023 | $265K | 4 |
| Q3 2023 | $280K | 4 |
| Q4 2023 | $210K | 4 |
| Q1 2024 | $257.5K | 4 |
| Q2 2024 | $227.5K | 4 |
| Q3 2024 | $207.5K | 4 |
| Q4 2024 | $187.5K | 4 |
| Q1 2025 | $248K | 4 |
| Q2 2025 | $276K | 3 |
| Q3 2025 | $216K | 4 |
| Q4 2025 | $386K | 4 |
| Q1 2026 | $296K | 4 |
| Q2 2026 | $226K | 3 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$745.8K · 57 reports
- Health issues$703.3K · 56 reports
- Medical research and clinical labs$695.8K · 55 reports
- Medicare and Medicaid$695.8K · 55 reports
- Taxation$628.2K · 40 reports
- Copyright, patent and trademark$401.7K · 15 reports
- Budget and appropriations$30K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES50 reports
- SENATE43 reports
- Health & Human Services, Dept of (HHS)24 reports
- Centers For Medicare and Medicaid Services (CMS)17 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseTravere Therapeutics | $2.4M | 15 quarters |
| Alston & Bird | $960K | 15 quarters |
| The Health Equity Strategies Group | $270.5K | 15 quarters |
| 2359 Strategies | $180K | 11 quarters |
| LMH Strategic Solutions | $50K | 3 quarters |
| Cornerstone Government Affairs | $30K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ALANNA TEMME | Legislative Director, U.S. Representative Jon Porter | Q4 2025 |
| ADAM NAVARA | Legislative Fellow, Rep. Jan Schakowsky. | Q2 2025 |
| CHARLES DUJON | Legislative Director (1998-2013), Rep. Jesse Jackson, Jr. | Q1 2025 |
| KARYN RICHMAN | Program Examiner, Executive Office of the President, Office of Management and Budget; Professional Staff, House Appropriations Committee | Q4 2022 |
| MARK MIODUSKI | Prof Staff; House Approps Cmte (Obey) | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/04for Q2 | The Health Equity Strategies Group | $16K |
| 07/20for Q2 | Alston & Bird | $70K |
| 07/20for Q2 | In-house | $140K |
| 05/19for Q1 | The Health Equity Strategies Group | $16K |
| 04/20for Q1 | Alston & Bird | $80K |
| 04/20for Q1 | In-house | $200K |
| 04/17for Q1 | LMH Strategic Solutions | Under $5,000 |
| 04/17for Q1 | LMH Strategic Solutions | $30K |
| 03/03for Q1 2025 | Alston & Bird | $60K |
| 02/20for Q4 2025 | The Health Equity Strategies Group | $16K |
| 01/20for Q4 2025 | Alston & Bird | $80K |
| 01/19for Q4 2025 | In-house | $260K |
| 01/12for Q4 2025 | LMH Strategic Solutions | $30K |
| 25/11/20for Q3 2025 | The Health Equity Strategies Group | $16K |
| 25/10/20for Q3 2025 | Alston & Bird | $70K |
| 25/10/20for Q3 2025 | LMH Strategic Solutions | $20K |
| 25/10/16for Q3 2025 | In-house | $110K |
| 25/08/28for Q3 2025 | LMH Strategic Solutions | Under $5,000 |
| 25/08/20for Q2 2025 | The Health Equity Strategies Group | $16K |
| 25/07/21for Q2 2025 | Alston & Bird | $60K |